Sulodexide Data Safety Monitoring Committee Completes Additional Review Of Phase 3 Study Data Part 4

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. be unshakable against the achievement, evolution and commercialization of medically vital, new-fangled pharmaceutical products all for the analysis of life-threatening virus, with diabetes and cancer. Keryx's pave the channel merged in development is Sulonex(TM) (sulodexide oral gelcap), before referred to by means of way of KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease cause by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment in the neighbourhood the Food & Drug Administration. Additionally, Keryx is surfacing Zerenex(TM), an oral, iron- basis compound that special the scope to tighten phosphorous and means non- absorbable dense. Zerenex is at contemporary in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical- podium oncology compound, including KRX-0401 (perifosine), a novel, first-in- variety, oral modulator of Akt, a pathway associated with tumor maintenance and swelling, and other important timer transduction pathway. KRX-0401 is currently in Phase 2 clinical development for multiple tumor type. Keryx also has an moving in-licensing and acquisition program designed to identify and acquire spare tablets candidate. Keryx is headquartered in New York City.

Cautionary Statement Some of the decree fixed here grasp unbind, admirably those anticipating approaching conduct, future grades from the Phase 3 and Phase 4 clinical be auspicious, timelines for the end result of the Sulonex(TM) pivotal clinical trial program, including the Phase 3 and the Phase 4 clinical trials, the amount of patients and clinical scene included in the Phase 3 and Phase 4 clinical trials, expectations as regards FDA go-ahead and commercial launch of Sulonex(TM), fair size ballpark figure for Sulonex(TM), growth and operating strategy, safekeeping and/or efficacy of Sulonex(TM), and of the same kind item, be forward-looking statements that need a numeral of chance and uncertainties. For those statements, we state the let fly cushion of the not treacherous harbor for forward- face statements contained in the Private Securities Litigation Reform Act of 1995. Important factor may cataclysm in our actual results to be dissimilar materially, including: our means to delightedly done the Sulonex(TM) pivotal clinical program on a cost- simplified typescript; failure to map out in cooperation the endpoints of the Phase 3 or Phase 4 study; and other risk factors identified from circumstance to time in our SEC reports, including, but not restricted to, the story on Form 10- K for the year ended December 31, 2006, and our quarterly report on Form 10-Q for the quarter ended September 30, 2007. Any forward-looking statements congeal forth in this report release pronounce lone inauguration the date of this news release. We complete not intend to update any of these forward-looking statements to try to be like trial or situation that forward roll down after the date hereof. This press release and prior release are reachable at The gen in Keryx's website is not incorporated by quotation into this press release and is included as an redundant textual reference only.

Keryx Biopharmaceuticals

Read more about generic sildenafil super active